ALGS

Aligos Therapeutics, Inc.

0.51 USD
-0.00 (-0.02%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Aligos Therapeutics, Inc. stock is down -26.1% since 30 days ago. The next earnings date is Aug 1, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 0% of the previous 3 June’s closed higher than May.

About Aligos Therapeutics, Inc.

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB)